comboprex 10 mg/160 mg/25 mg filmdragerad tablett
dymalife pharmaceutical s.r.l. - amlodipinbesilat; hydroklortiazid; valsartan - filmdragerad tablett - 10 mg/160 mg/25 mg - valsartan 160 mg aktiv substans; amlodipinbesilat 13,86 mg aktiv substans; hydroklortiazid 25 mg aktiv substans; laktosmonohydrat hjälpämne
comboprex 10 mg/160 mg/12,5 mg filmdragerad tablett
dymalife pharmaceutical s.r.l. - amlodipinbesilat; hydroklortiazid; valsartan - filmdragerad tablett - 10 mg/160 mg/12,5 mg - amlodipinbesilat 13,86 mg aktiv substans; hydroklortiazid 12,5 mg aktiv substans; valsartan 160 mg aktiv substans; laktosmonohydrat hjälpämne
amlodipin/valsartan/hydroklortiazid denk 5 mg/160 mg/12,5 mg filmdragerad tablett
denk pharma gmbh & co kg - amlodipinbesilat; hydroklortiazid; valsartan - filmdragerad tablett - 5 mg/160 mg/12,5 mg - amlodipinbesilat 6,94 mg aktiv substans; valsartan 160 mg aktiv substans; hydroklortiazid 12,5 mg aktiv substans
amlodipin/valsartan/hydroklortiazid denk 10 mg/320 mg/25 mg filmdragerad tablett
denk pharma gmbh & co kg - amlodipinbesilat; hydroklortiazid; valsartan - filmdragerad tablett - 10 mg/320 mg/25 mg - valsartan 320 mg aktiv substans; amlodipinbesilat 13,88 mg aktiv substans; hydroklortiazid 25 mg aktiv substans
triaprexion 5 mg/160 mg/12,5 mg filmdragerad tablett
dymalife pharmaceutical s.r.l. - amlodipinbesilat; hydroklortiazid; valsartan - filmdragerad tablett - 5 mg/160 mg/12,5 mg - hydroklortiazid 12,5 mg aktiv substans; amlodipinbesilat 6,94 mg aktiv substans; valsartan 160 mg aktiv substans
triaprexion 10 mg/320 mg/25 mg filmdragerad tablett
dymalife pharmaceutical s.r.l. - amlodipinbesilat; hydroklortiazid; valsartan - filmdragerad tablett - 10 mg/320 mg/25 mg - hydroklortiazid 25 mg aktiv substans; valsartan 320 mg aktiv substans; amlodipinbesilat 13,88 mg aktiv substans
tysabri
biogen netherlands b.v. - natalizumab - multipel skleros - selektiva immunsuppressiva medel - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 och 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.
cabergoline ratiopharm 0,5 mg tablett
ratiopharm gmbh - kabergolin - tablett - 0,5 mg - laktos (vattenfri) hjälpämne; kabergolin 0,5 mg aktiv substans - kabergolin
anivo 300 mg kapsel, hård
ebb medical ab - gabapentin - kapsel, hård - 300 mg - propylenglykol hjälpämne; para-orange hjälpämne; gabapentin 300 mg aktiv substans
anivo 400 mg kapsel, hård
ebb medical ab - gabapentin - kapsel, hård - 400 mg - gabapentin 400 mg aktiv substans; propylenglykol hjälpämne